Results 201 to 210 of about 263,699 (331)
Epidemiology of hospitalized heart failure in France based on national data over 10 years, 2012–2022
ESC Heart Failure, Volume 12, Issue 2, Page 1283-1294, April 2025.Abstract Aims
We aim to describe the incidence of HF hospitalization in France in the post‐pandemic era, the prevalence of HF cases and patients' characteristics, management and outcomes while focusing on sex, age and socio‐economic differences and to analyse time‐trends between 2012 and 2022.Valérie Olié, Richard Isnard, Françoise Pousset, Clémence Grave, Jacques Blacher, Amélie Gabet +5 morewiley +1 more sourceGlobal patterns of polypharmacy after acute heart failure hospitalization: Prevalence and outcomes from the REPORT‐HF registry
European Journal of Heart Failure, EarlyView.Global patterns of polypharmacy after acute heart failure hospitalization. GDMT, guideline‐directed medical therapy; HF, heart failure. Aims
Polypharmacy, defined as the concurrent use of ≥5 medications, is prevalent among older adults with heart failure (HF).Wan Ting Tay, Tiew‐Hwa Katherine Teng, Wouter Ouwerkerk, John G.F. Cleland, Sean P. Collins, Christiane E. Angermann, Kenneth Dickstein, Ulf Dahlstrom, Anja Schweizer, Achim Obergfell, Kai‐Hang Yiu, Mathieu Ghadanfar, Mahmoud Hassanein, Qing‐Wen Ren, Wen‐Li Gu, Georg Ertl, Sergio V. Perrone, Gerasimos Filippatos, Carolyn S.P. Lam, Jasper Tromp +19 morewiley +1 more sourceContemporary medical therapy for heart failure across the ejection fraction spectrum: The OPTIPHARM‐HF registry
European Journal of Heart Failure, EarlyView.Medical therapy use across the left ventricular ejection fraction spectrum in the OPTIPHARM‐HF registry. ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor–neprilysin inhibitor; GDMT, guideline‐directed medical therapy; HF, heart failure; HFmrEF, heart failure with mildly reduced ejection ...Riccardo M. Inciardi, Maurizio Volterrani, Gianluigi Savarese, Muthiah Vaduganathan, Chiara Oriecuia, Carlo M. Lombardi, Cristina Gussago, Piergiuseppe Agostoni, Pietro Ameri, Giuseppe Armentaro, Chiara Arzilli, Nadia Aspromonte, Andrea Attanasio, Roberto Badagliacca, Lucia Barbieri, Pier Paolo Bocchino, Francesca Bursi, Matteo Cameli, Martino Canonero, Jeness S. Campodonico, Teresa Capovilla, Erberto Carluccio, Stefano Carugo, Vincenzo Castiglione, Dario Catapano, Manlio Cipriani, Michele Correale, Domenico D'Amario, Raffaele De Caterina, Gaetano M. De Ferrari, Emilia D'Elia, Luca Di Odoardo, Michele Emdin, Luigi Falco, Giulia Ferrante, Alessandra Fornaro, Paolo Fornaro, Gionata Guastamiglio, Marco Guazzi, Massimo Iacoviello, Massimo Imazio, Enrico Incaminato, Maria Teresa La Rovere, Sergio Leonardi, Marta Maccallini, Giulia E. Mandoli, Daniele Masarone, Marco Masetti, Alberto Mazzoni, Marta Mazzotta, Marco Merlo, Luigi Moschini, Filippo Novarese, Alberto Palazzuoli, Maria C. Pastore, Giuseppe Patti, Roberto F.E. Pedretti, Stefano Pidello, Massimo F. Piepoli, Giuseppe Pinto, Luciano Potena, Claudia Raineri, Filippo M. Rubbo, Mario Sabatino, Andrea Salzano, Angela Sciacqua, Michele Senni, Paolo Severino, Gianfranco Sinagra, Barbara Sposato, Stefano Taddei, Alessandro Valleggi, Carlo Vignati, Dario Vizza, Claudia Specchia, Giuseppe Rosano, Marco Metra, on behalf of the OPTIPHARM‐HF investigators, Marianna Adamo, Marilisa Ambrosio, Paolo Biagioli, Valeria Borelli, Natale Brunetti, Margherita Calcagnino, Giuseppe Caminiti, Francesco Canonico, Angelo Caporotondi, Velia Cassano, Ali Chraim, Valentina Codazzi, Giuliana Cimino, Francesco Clemenza, Giuditta Cuccuru, Giulia De Lio, Giandomenico Disabato, Marcello Divino, Salvatore D'Isa, Roberta Famiani, Enrica Fede, Letizia Fiòorentino, Alberto Foa', Paolo Fornaro, Noemi Furlotti, Nicolò Gallingani, Alberto Genova, Stefano Ghio, Federico Gobbi, Daniela Grassano, Lucia Guerisoli, Manuela Iseppi, Simona Leone, Ferdinando Loiacono, Valeria Luberto, Rossella Manai, Niccolò Manetti, Lina Manzi, Fabio Marsico, Francesco Maruca, Gabriele Masini, Irene Mattavelli, Ciro Mauro, Alberto Mazzoni, Marta Mazzotta, Pierre Meynet, Valentina Morsella, Giulia Nemola, Martina Niccolai, Savina Nodari, Matteo Pagnesi, Gianpaolo Palmieri, Alberto Panza, Francesca Parisi, Carlo Alberto Pastura, Anna Lisa Picerni, Riccardo Pilia, Ilaria Pirrone, Nicola R. Pugliese, Claudio Puteo, Federica Ramani, Gloria Santangelo, Laura Scelsi, Edoardo Sciatti, Lorenza Sforzini, Giulia Spoto, Davide Stolfo, Roberto Tarantini, Maria Cristina Tavera, Floriana Tortomasi, Eduardo Valente, Giuseppe Varricchione, Enrico Vizzardi, Greta Zagni, Mattia Zampieri +152 morewiley +1 more sourceAdherence to guideline‐directed medical treatments in heart failure. A scientific statement of the Heart Failure Association (HFA) of the ESC and the ESC Working Group on Cardiovascular Pharmacotherapy
European Journal of Heart Failure, EarlyView.Heart failure (HF) affects over 60 million individuals globally. Contemporary guideline‐directed medical therapies (GDMT) reduce cardiovascular mortality and HF hospitalizations. However, medication non‐adherence represents a critical barrier limiting real‐world efficacy of GDMT.Gianluigi Savarese, Felix Lindberg, Antonio Cannata, Marianna Adamo, Giuseppe Ambrosio, Pietro Ameri, Markus S. Anker, Magnus Bäck, Antoni Bayes‐Genis, Tuvia Ben Gal, Frieder Braunschweig, Ovidiu Chioncel, Emilia D'Elia, Hassan El‐Tamimi, Gerasimos Filippatos, Nicolas Girerd, Loreena Hill, Ewa Jankowska, Kamlesh Khunti, Basil S. Lewis, Brenda Moura, Offer Amir, Stefania Paolillo, Massimo Piepoli, Abdulla Shehab, Maggie Simpson, Hadi Skouri, Davide Stolfo, Carlo Gabriele Tocchetti, Cristiana Vitale, Maurizio Volterrani, Stephan von Haehling, Sven Wassmann, Mehmet Birhan Yilmaz, Juan Carlos Kaski, Dobromir Dobrev, Marco Metra, Giuseppe M.C. Rosano +37 morewiley +1 more source
